Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07228078
PHASE2

Open-Label Extension Protocol to SNK01-AD01 Study

Sponsor: NKGen Biotech, Inc.

View on ClinicalTrials.gov

Summary

Open-Label Extension Protocol to SNK01-AD01 Study

Official title: An Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Alzheimer's Disease (Study SNK01-AD02)

Key Details

Gender

All

Age Range

40 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-06-30

Completion Date

2028-04

Last Updated

2025-11-13

Healthy Volunteers

No

Interventions

BIOLOGICAL

SNK01

SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug

Locations (1)

Behavioral Research Specialists, LLC

Glendale, California, United States